Cannabinoids, Neural Synchrony, and Information Processing
This trial is active, not recruiting.
|Conditions||cannabis, psychotic disorders|
|Collaborator||National Institute on Drug Abuse (NIDA)|
|Start date||April 2008|
|End date||December 2017|
|Trial size||36 participants|
|Trial identifier||NCT00708994, 0803003638, 5R21DA020750-02|
The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG).
|Intervention model||crossover assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
|Primary purpose||basic science|
time frame: +30
Clinician Administered Dissociative Symptoms Scale, Positive and Negative Symptom Scale, Visual Analog Scale
time frame: Baseline, +10, +80
Male or female participants from 18 years up to 55 years old.
Inclusion Criteria: - Men and women aged 18 and 55 years (extremes included) on the day of the first dosing. - Exposed to cannabis at least once. Exclusion Criteria: 1. Cannabis naïve 2. Positive pregnancy screen during screening 3. Hearing deficits
|Official title||Cannabinoids, Psychosis, Neural Synchrony, and Information Processing|
|Principal investigator||Deepak D'Souza, MD|
Call for more information